Expression of Fas and Fas Ligand in Hodgkin's Disease

References

• Diehl V., von Kalle C., Fonatsch C., Tesch H., Juecker M., Schaadt M. The cell of origin in Hodgkin's disease. Seminars in Oncology 1990; 17: 660–672
   PubMed Web of Science ®Google Scholar
• Hansen N. E., Karle H. The elusive Hodgkin cell. Scandinavian Journal of Haematology 1981; 26: 353–378
   PubMedGoogle Scholar
• Jaffe E. S. The elusive Reed‐Sternberg cell. New England Journal of Medicine 1989; 320: 529–531
   PubMed Web of Science ®Google Scholar
• Poppema S. The nature of the lymphocytes surrounding Reed‐Sternberg cells in nodular lymphocyte predominance and in other types of Hodgkin's Disease. American Journal of Pathology 1989; 135: 351–357
   PubMed Web of Science ®Google Scholar
• Xerri L., Carbuccia N., Pare P., Hassoun J., Birg F. Frequent expression of Fas/Apo‐1 in Hodgkin's Disease and Anaplastic Large Cell Lymphomas. Histopathology 1995; 27: 235–241
   PubMed Web of Science ®Google Scholar
• Nguyen P. L., Harris N. L., Ritz J., Robertson M. J. Expression of CD95 antigen and bcl‐2 protein in Non‐hodgkin's lymphomas and Hodgkin's Disease. American Journal of Pathology 1996; 148: 847–854
   PubMed Web of Science ®Google Scholar
• Smith C. A., Farah T., Goodwin R. G. The TNF receptor superfamily of cellular and viral proteins : activa‐tion.co‐stimulation and deadth. Cell 1994; 76: 959–962
   PubMed Web of Science ®Google Scholar
• Nagata S., Golstein P. The Fas deadth factor. Science 1995; 267: 1449–1456
   PubMed Web of Science ®Google Scholar
• Suda T., Okazaki T., Naito Y., Yokota T., Arai N., Ozaki S., Nakao K., Nagata S. Expression of Fas ligand in T‐cell lineage. Journal of Immunology 1995; 154: 3806–3813
   PubMed Web of Science ®Google Scholar
• Vignaux F., Vivier E., Malissen B., Nagata S., Golstein P. TCR / CD3 coupling to Fas based cytotoxicity. Journal of Experimental Medicine 1995; 181: 781–786
   PubMed Web of Science ®Google Scholar
• Lan H. Y., Mu W., Nikolic‐Paterson D. J., Atkins R. C. A novel, simple, reliable, and sensitive method for multiple immunoenzyme staining: use of microwave owen heating to block antibody cross‐reactivity and retreive antigens. Journal of Histochemistry. Cytochemistry 1995; 43: 97–102
   PubMed Web of Science ®Google Scholar
• Lukes R., Butler J., Hicks E. Natural history of Hodgkin's disease as related to its pathological picture. Cancer 1966; 19: 317–344
   Web of Science ®Google Scholar
• Xerri L., Devillard E., Hassoun J., Bouabdullah R., Car‐buccia N., Birg F. Expression of Fas Ligand is rarely detectable by RT‐PCR in malignant lymphomas, but is high in human tissues acting as immunological sanctuaries. Annals of Oncology 1996; 7(supplement 3), abstract number 303, International conference on malignant lymphomas, Switzerland, June, 1996
   Google Scholar
• Zhao S., Kliche K. O., Clodi K., Cabanillas E., Andreef M., Younes A. Nodal T‐lymphocytes of Hodgkin's Disease have low expression of Fas Ligand and CD30 Ligand which can be upregulated by IFN‐alpha and anti‐CD3 antibody. Blood 1996; 88, no. 10, supplement no. 1, part 1, abstract number 2668, 670a, American Soceity of Haematology annual meeting, Dec. 1996
   Web of Science ®Google Scholar
• Kiener P. A., Davis P. M., Rankin B. M., Klebanoff S. J., Ledbetter J. A., Starling G. C., Liles W. C. Human Monocytic cells contain high levels of intracellular Fas Ligand, Rapid release following cellular activation. Journal of Immunology 1997; 159: 1594–1598
   PubMed Web of Science ®Google Scholar
• Lorenzen J., Thiele J., Fischer R. The mummified Hodgkin cell: Cell death in Hodgkin's disease. Journal of Pathology 1997; 182: 288–298
   PubMed Web of Science ®Google Scholar
• Owen‐Schaub L. B., Yonehara S., Crump W. L., Grimm E. A. DNA fragmentation and cell death is selectively triggered in activated lymphocytes by Fas antigen engagement. Cellular Immunology 1992; 140: 197–205
   PubMed Web of Science ®Google Scholar
• Hahne M. L., Rimoldi D., Schroter M., Romero P., Schreier M., French L. E., Schneider P., Bornand T., Fontana A., Lienard D., Cerottini J. C., Tschopp J. Melanoma cell expression of Fas Ligand : Implications for tumor immune escape. Science 1996; 274: 1363–1366
   PubMed Web of Science ®Google Scholar
• Papoff G., Cascino I., Eramo A., Starace G., Lynch D. H., Ruberti G. An N‐terminal domain shared by Fas/Apo‐1 (CD95) soluble variants prevents cell deadth in vitro. Journal of Immunology 1996; 156: 4622–4630
   PubMed Web of Science ®Google Scholar
• Su X., Zhou X., Wang Z., Yang P., Jope R. S., Mountz J. D. Defective expression of hematopoietic cell protein tyrosine phosphatase (HCP) in lymphoid cell blocks Fas mediated apoptosis. Immunity 1995; 2: 353–357
   PubMed Web of Science ®Google Scholar
• Sato T., Irie S., Kitada S., Reed J. C. FAP‐1: a protein tyrosine phosphatase that associates with Fas. Science 1995; 268: 411–415
   PubMed Web of Science ®Google Scholar
• Cascino I., Papoff G., De Maria R., Testi R., Ruberti G. Fas / Apo‐1 / CD95 receptor lacking the intracyto‐plasmic signalling domain protects tumor cells from Fas‐mediated apoptosis. Journal of Immunology 1996; 156: 13–17
   PubMed Web of Science ®Google Scholar
• Tepper C. G., Jayadev S., Liu B., Bielawska A., Wolff R., Yonehara S., Hannun Y. A., Seldin M. F. Role of ceramide as an endogenous mediator of Fas ‐ induced cyto‐toxicity. Proceedings of the National Academy of Sciences USA 1995; 92: 8443–8447
   PubMed Web of Science ®Google Scholar
• Fisher G. H., Rosenberg F. J., Straus S. E., Dale J. K., Midolelton L. A., Lin A. Y., Strober W., Lenardo M. J., Puck J. M. Dominant interfering fas gene mutations impair apoptosis in a human autoimmune lymphoprolifera‐tive syndrome. Cell 1995; 81: 935–946
   PubMed Web of Science ®Google Scholar